Neurogene (NGNE) Price & Analysis

Compare

565 Followers

NGNE Stock Chart & Stats

Day’s Range― - ―

52-Week Range$6.88 - $74.49

Previous CloseN/A

Volume20.02K

Average Volume (3M)130.72K

Market Cap

$249.04M

Enterprise Value$51.22M

Total Cash (Recent Filing)$274.52M

Total Debt (Recent Filing)$10.97M

Price to Earnings (P/E)―

Beta2.99

Next Earnings

Nov 24, 2025

EPS Estimate

-1.25

Next Dividend Ex-DateN/A

Dividend YieldN/A

Share Statistics

EPS (TTM)-1.05

Shares Outstanding14,271,916

10 Day Avg. Volume171,956

30 Day Avg. Volume130,721

Financial Highlights & Ratios

PEG RatioN/A

Price to Book (P/B)N/A

Price to Sales (P/S)N/A

P/FCF RatioN/A

Enterprise Value/Market Cap0.21

Enterprise Value/Revenue-55.38

Enterprise Value/Gross Profit-16.09

Enterprise Value/Ebitda-0.63

Forecast

1Y Price Target

$46.75

Price Target Upside168.06% Upside

Rating ConsensusStrong Buy

Number of Analyst Covering7

Bulls Say, Bears Say

Bulls Say

Financial StabilityCash reserves at the end of the period were $274.5M, expected to provide financial runway into early 2028, indicating strong financial planning.

Regulatory ProgressThe FDA is expected to approve the protocol and statistical analysis plan for Embolden in the future, paving the way for the company to begin treating patients in the trial.

Safety ProfileNo evidence of HLH/hyperinflammatory syndrome has been reported at the current dose level of '401, indicating a favorable safety profile.

Bears Say

Financial PerformanceThe net loss reported was $22M, which could be a concern for financial stability.

Regulatory RequirementsThe FDA advised that a 6-month endpoint would not be considered clinically meaningful, requiring the study to focus on a 12-month primary endpoint.

Neurogene News

Short Report: Viking Therapeutics short interest at 5-year high after VK273 data

Welcome to this week’s installment of “The Short Interest Report” – The Fly’s weekly recap of short interest...

25d ago

SMR

MLTX

Neurogene’s Clinical Progress and Financial Resilience Underpin Buy Rating Despite Regulatory Challenges

Analyst Mani Foroohar of Leerink Partners reiterated a Buy rating on Neurogene, with a price target of $70.00....

1M ago

NGNE

Positive Outlook for Neurogene: Buy Rating Affirmed Amid Clinical Progress and Strong Financial Position

TD Cowen analyst Ritu Baral has maintained their bullish stance on NGNE stock, giving a Buy rating yesterday....

1M ago

NGNE

Neurogene’s NGN-401 Gains Favorable Buy Rating Amid Promising Trial Design and Strong Safety Profile

Analyst Mitchell Kapoor of H.C. Wainwright reiterated a Buy rating on Neurogene, retaining the price target of $45.00....

1M ago

NGNE

Neurogene Inc. Reports Increased Losses Amid R&D Focus

Neurogene Inc. ( ($NGNE) ) has released its Q2 earnings. Here is a breakdown of the information Neurogene...

1M ago

NGNE

Neurogene Advances NGN-401 Gene Therapy for Rett Syndrome

An announcement from Neurogene ( ($NGNE) ) is now available. Neurogene Inc. announced significant progress in its NGN-401...

1M ago

NGNE

NGNE Upcoming Earnings Report: What to Expect?

Neurogene Inc. (NGNE) is scheduled to report 2nd quarter earnings on 08/08/2025. Regarding Q2 estimates, Wall Street analysts...

1M ago

NGNE

Promising Prospects for Neurogene in Rett Syndrome Treatment: Buy Rating Affirmed

Leerink Partners analyst Mani Foroohar has maintained their bullish stance on NGNE stock, giving a Buy rating yesterday....

3M ago

NGNE

Optimistic Outlook for Neurogene’s NGN-401 in Rett Syndrome Treatment Boosts Buy Rating

In a report released yesterday, Evan Seigerman from BMO Capital maintained a Buy rating on Neurogene (NGNE –...

3M ago

NGNE

Neurogene’s Promising Trial Design and Safety Profile Earns Buy Rating from Analyst Mitchell Kapoor

Neurogene (NGNE – Research Report), the Healthcare sector company, was revisited by a Wall Street analyst today. Analyst...

3M ago

NGNE

Promising Advancements in Neurogene’s Gene Therapy for Rett Syndrome Drive Buy Rating

William Blair analyst Sami Corwin has reiterated their bullish stance on NGNE stock, giving a Buy rating on...

3M ago

NGNE

Neurogene says on track to share updated clinical efficacy and safety data

In addition to its update on registrational trial design for Embolden study, the company states: “Neurogene (NGNE) previously...

3M ago

NGNE

Neurogene announces registrational trial design for Embolden study of NGN-401

Neurogene (NGNE) “announced details of Embolden, the Company’s registrational clinical trial designed to evaluate NGN-401 gene therapy for...

3M ago

NGNE

Craig-Hallum bullish on Neurogene, initiates with a Buy

As previously reported, Craig-Hallum analyst Albert Lowe initiated coverage of Neurogene (NGNE) with a Buy rating and $50...

3M ago

NGNE

TSHA

NGNE FAQ

What was Neurogene’s price range in the past 12 months?

Neurogene lowest stock price was $6.88 and its highest was $74.49 in the past 12 months.

What is Neurogene’s market cap?

Neurogene’s market cap is $249.04M.

When is Neurogene’s upcoming earnings report date?

Neurogene’s upcoming earnings report date is Nov 24, 2025 which is in 67 days.

How were Neurogene’s earnings last quarter?

Neurogene released its earnings results on Aug 11, 2025. The company reported -$1.05 earnings per share for the quarter, beating the consensus estimate of -$1.16 by $0.11.

Is Neurogene overvalued?

According to Wall Street analysts Neurogene’s price is currently Undervalued. Get more investment ideas with TipRanks Premium

Does Neurogene pay dividends?

Neurogene does not currently pay dividends.

What is Neurogene’s EPS estimate?

Neurogene’s EPS estimate is -1.25.

How many shares outstanding does Neurogene have?

Neurogene has 14,271,916 shares outstanding.

What happened to Neurogene’s price movement after its last earnings report?

Neurogene reported an EPS of -$1.05 in its last earnings report, beating expectations of -$1.16. Following the earnings report the stock price went down -5.553%.

Which hedge fund is a major shareholder of Neurogene?

Currently, no hedge funds are holding shares in NGNE

Neurogene Stock Smart Score

Underperform

Fundamentals

Return on Equity

-39.41%

Trailing 12-Months

Asset Growth

65.34%

Trailing 12-Months

Top Smart Score Stocks >

Company Description

Neurogene

Neurogene (NGNE) is a biotechnology company focused on developing life-changing genetic medicines to address severe neurological diseases. The company operates within the healthcare and biotechnology sectors, leveraging cutting-edge gene therapy techniques to create innovative treatments that have the potential to transform patient outcomes.

Neurogene (NGNE) Earnings & Revenues

Historic Earnings Reports

NGNE Stock 12 Month Forecast

Average Price Target

$46.75

▲(168.06% Upside)

{"navigator":{"disabled":true},"exporting":{"enabled":false},"title":{"text":null},"chart":{"height":200,"style":{"fontFamily":"Roboto Flex, -apple-system, BlinkMacSystemFont, Segoe UI, Roboto, Helvetica, Arial, sans-serif, Apple Color Emoji, Segoe UI Emoji, Segoe UI Symbol","fontWeight":"400","color":"#5d5d5e"},"spacingTop":30,"spacingRight":60,"events":null},"yAxis":{"labels":{"style":{"color":"inherit"},"distance":6,"x":-6,"y":-6,"zIndex":1,"map_label_formatter":{"8":"$8","71":"$71","23.75":"$23.8","39.5":"$39.5","55.25":"$55.3"}},"plotLines":[{"color":"rgba(0,0,0,0)","value":70,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":-10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-bottom flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#199ca5\">High </span>\n\n  <span style=\"color:#199ca5\">$70.00</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":46.75,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":0,"text":"<div  class=\"positionrelative hoverZ3 triangleleft flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#828080\">Average </span>\n\n  <span style=\"color:#828080\">$46.75</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":26,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-top flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#912767\">Low </span>\n\n  <span style=\"color:#912767\">$26.00</span>\n  </div></div>","useHTML":true}}],"tickPositions":[8,23.75,39.5,55.25,71],"lineColor":"#dddddd","gridLineWidth":1,"gridLineColor":"#dddddd","lineWidth":1,"title":{"text":""}},"plotOptions":{"series":{"states":{"inactive":{"opacity":1}}},"line":{"animation":{"duration":0},"dataLabels":{"allowOverlap":true},"borderWidth":1,"marker":{"enabled":true,"fillColor":"#FFFFFF","radius":3,"lineWidth":2,"symbol":"circle","lineColor":"#828080"}}},"xAxis":{"labels":{"style":{"color":"inherit"},"rotation":0,"map_label_formatter":{"3":"Nov<br/>2024","6":"Feb<br/>2025","9":"May<br/>2025","12":"Aug<br/>2025","25":"Aug<br/>2026"}},"tickPositions":[3,6,9,12,25],"plotLines":[{"color":"#dddddd","width":1,"value":12},{"color":"#dddddd","width":1,"value":12}],"lineWidth":0,"gridLineWidth":1,"gridLineColor":"#dddddd","tickLength":0},"legend":{"symbolRadius":0,"symbolPadding":4,"symbolHeight":14,"borderWidth":0,"symbolWidth":14,"align":"left","verticalAlign":"bottom","enabled":false},"tooltip":{"backgroundColor":"rgba(0,0,0,0)","useHTML":true,"borderWidth":0,"borderColor":"rgba(0,0,0,0)","padding":0,"shadow":null,"headerFormat":"","footerFormat":"","pointFormat":"<div class=\"flexccc lineHeight2 bgwhite shadow2 px3 py3 radiismall fonth10_semibold\">\n                <span class=\"colorgray-3 mb4\">{point.date:%b %d ,%Y}</span>\n                <span>Analyst Consensus</span>\n                {point.info}\n          </div>\n           </div>"},"credits":{"enabled":false},"accessibility":{"description":""},"responsive":{"rules":[{"chartOptions":{"chart":{"spacing":[0,0,0,0],"margin":[30,60,40,5]},"xAxis":{"tickPositions":[3,12,25.25]},"yAxis":{"labels":{"enabled":false}},"title":{"text":null},"subtitle":{"text":null}},"condition":{"maxWidth":500}}]},"series":[{"lineWidth":2,"dashStyle":"ShortDash","name":"High","type":"line","color":"#199ca5","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,21.78,25.48923076923077,29.19846153846154,32.90769230769231,36.61692307692308,40.326153846153844,44.035384615384615,47.744615384615386,51.45384615384616,55.16307692307692,58.87230769230769,62.581538461538464,66.29076923076923,{"y":70,"marker":{"fillColor":"#199ca5","lineColor":"#199ca5","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Average","type":"line","color":"#828080","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,21.78,23.700769230769232,25.621538461538464,27.542307692307695,29.463076923076926,31.383846153846157,33.30461538461539,35.22538461538461,37.14615384615385,39.066923076923075,40.98769230769231,42.90846153846154,44.82923076923077,{"y":46.75,"marker":{"fillColor":"#828080","lineColor":"#828080","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Low","type":"line","color":"#912767","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,21.78,22.104615384615386,22.42923076923077,22.753846153846155,23.07846153846154,23.403076923076924,23.72769230769231,24.052307692307693,24.376923076923077,24.701538461538462,25.026153846153846,25.35076923076923,25.675384615384615,{"y":26,"marker":{"fillColor":"#912767","lineColor":"#912767","enabled":true,"symbol":"circle"}}]},{"type":"line","data":[{"y":40.62,"date":1719792000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 18,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":40.51,"date":1722470400000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 19,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":39.94,"date":1727740800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 11,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":46.07,"date":1730419200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 25,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 7</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":24.57,"date":1733011200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 20,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 7</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":22.86,"date":1735689600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 18,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 9</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":15.85,"date":1738368000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 4,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 2</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":17.69,"date":1740787200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 8,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 3</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":9.66,"date":1743465600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Moderate Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 9,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 6</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":15.4,"date":1746057600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 16,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 1, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 7</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":17.75,"date":1748736000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 16,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 1, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 6</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":19.19,"date":1751328000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 21,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 1, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 1</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":21.78,"date":1754006400000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 18,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"fillColor":"black","lineColor":"black","enabled":true,"symbol":"circle"}},null,null,null,null,null,null,null,null,null,null,null,null],"color":"#0666a7"}]}

Detailed Analyst Forecast >